HCW Biologics Toekomstige groei
Future criteriumcontroles 2/6
HCW Biologics's earnings are forecast to decline at 2.5% per annum while its annual revenue is expected to grow at 78.1% per year. EPS is expected to grow by 13.3% per annum.
Belangrijke informatie
-2.5%
Groei van de winst
13.3%
Groei van de winst per aandeel
| Biotechs winstgroei | 27.1% |
| Inkomstengroei | 78.1% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 22 Jul 2024 |
Recente toekomstige groei-updates
Geen updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -38 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -30 | N/A | N/A | 1 |
| 12/31/2024 | 1 | -26 | N/A | N/A | 1 |
| 6/30/2024 | 4 | -38 | -22 | -18 | N/A |
| 3/31/2024 | 4 | -27 | -29 | -22 | N/A |
| 12/31/2023 | 3 | -25 | -29 | -23 | N/A |
| 9/30/2023 | 3 | -20 | -25 | -22 | N/A |
| 6/30/2023 | 4 | -19 | -31 | -19 | N/A |
| 3/31/2023 | 4 | -18 | -23 | -12 | N/A |
| 12/31/2022 | 7 | -15 | -21 | -10 | N/A |
| 9/30/2022 | 5 | -13 | -20 | -10 | N/A |
| 6/30/2022 | 4 | -12 | -13 | -13 | N/A |
| 3/31/2022 | 3 | -12 | -11 | -11 | N/A |
| 12/31/2021 | N/A | -13 | -11 | -11 | N/A |
| 9/30/2021 | 4 | -8 | -11 | -11 | N/A |
| 6/30/2021 | 4 | -8 | -9 | -9 | N/A |
| 3/31/2021 | 4 | -8 | -10 | -10 | N/A |
| 12/31/2020 | 4 | -7 | -11 | -10 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: HCWB is forecast to remain unprofitable over the next 3 years.
Winst versus markt: HCWB is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: HCWB is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: HCWB's revenue (78.1% per year) is forecast to grow faster than the US market (8.9% per year).
Hoge groei-inkomsten: HCWB's revenue (78.1% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if HCWB's Return on Equity is forecast to be high in 3 years time